Introduction {#Sec1}
============

Hepatocellular carcinoma (HCC) remains one of the most common indications for liver transplantation^[@CR1]^. The Milan criteria defined transplant eligibility for HCC patients for more than two decades; however, the limits are now being expanded according to morphological and biological tumour features^[@CR2]--[@CR6]^. Nevertheless, discussion on widening the pool of potential candidates is controversial owing to a major and relatively constant shortage of deceased donors. Further expansion of the selection criteria will inevitably lead to increased waiting times for both HCC and non-HCC populations. In HCC patients, markedly prolonged times on the waiting list are characterised by more common dropouts, possibly leading to the development of more aggressive tumours^[@CR7]^. Owing to increased rates of listing and privileged positions of HCC patients under the current allocation policies, a higher number of HCC transplant candidates may have even more detrimental effects on non-HCC patients' waiting times and pre-transplant mortality^[@CR8],[@CR9]^. Because widening the donor pool with living donors and high-risk or extended criteria deceased donors is a common strategy, it appears to have major relevance, particularly for HCC patients.

Experimental studies demonstrate the increased risk of cancer recurrence associated with ischemia-reperfusion injury (IRI)^[@CR10],[@CR11]^. Changes in hepatic microenvironment caused by IRI promote seeding and the development of metastases, whereas IRI-induced proinflammatory response, release of growth factors, mobilization of progenitor cells, and transformation of cancer cells to more aggressive phenotypes may potentiate the formation and growth of metastases at both local and remote sites^[@CR12]--[@CR16]^. Because grafts procured from high-risk deceased donors and to a lesser extent, partial grafts procured from living donors may be more susceptible to IRI, the use of these grafts may increase the risk of post-transplant HCC recurrence. This hypothesis was subject to numerous studies with inconsistent results. Although transplantations of grafts procured from living donors or high-risk grafts procured from deceased donors after cardiac death or those who were older and had hepatic steatosis or other risk factors were reported to have adverse effects on outcomes after liver transplantations for HCC in several studies, the results of available studies are not completely consistent^[@CR17]--[@CR23]^. However, recent reports found that prolonged ischemic times, directly related to the magnitude of IRI, increased the risk of post-transplant HCC recurrence^[@CR24],[@CR25]^. Nevertheless, data on the direct effect of the magnitude of IRI on the risk of HCC recurrence after deceased donor liver transplantation are limited. Therefore, this study aimed to evaluate the association between the degree of graft IRI as indicated by post-reperfusion transaminase and lactate dehydrogenase (LDH) levels and the risk of post-transplant HCC recurrence after deceased donor liver transplantation with respect to patients' initial risk profile.

Methods {#Sec2}
=======

This was a retrospective observational study. In total, 250 liver transplantations were performed for HCC patients between January 2001 and June 2016 at the Department of General, Transplant and Liver Surgery (Medical University of Warsaw). Patients with fibrolamellar HCCs and those with combined HCC/cholangiocarcinoma were not included. After exclusion of 55 patients with missing measurements of transaminase levels 2 h after reperfusion, the final study cohort comprised 195 liver transplant recipients. The study protocol was approved by the institutional review board of the Medical University of Warsaw. Informed consents were not obtained from the patients due to the retrospective nature of the study, which is in line with institutional review board and national regulations. All methods were performed in accordance with the relevant guidelines and regulations. No organs were procured from prisoners.

The degree of IRI was represented by three variables, namely, serum alanine transaminase (ALT), serum aspartate transaminase (AST), and serum LDH levels; each was assessed from a blood sample obtained 2 h after portal reperfusion. These variables were the primary factors of interest. Peak serum bilirubin concentration, international normalised ratio (INR), and gamma-glutamyl transpeptidase (GGTP) activity over the first 7 post-transplant days were additionally analysed as variables associated with IRI. The duration of cold and warm ischemia was defined as the time from clamping of the donor aorta until the removal of the graft from the preservation solution and that from the removal of the graft from the cold preservation solution until portal reperfusion, respectively. The sum of cold and warm ischemic times formed the total ischemic time. All grafts were procured from donors after brain death. Tumour recurrence over the 5-year post-transplant observation period was the primary end-point. Recurrence-free survival was calculated from the date of transplantation until tumour recurrence and censored at the date of last available follow-up, death for non-HCC related causes or 5 years post-transplantation (whichever occurred first). Details on the surgical technique, perioperative care, immunosuppression, and follow-up protocol are provided elsewhere^[@CR26],[@CR27]^.

First, post-reperfusion ALT, AST, and LDH levels were assessed for their potential effect on the risk of post-transplant tumour recurrence in all patients. Other independent predictors of recurrence were also assessed, including peak post-transplant bilirubin concentration, INR, and GGTP activity. Furthermore, the analyses were adjusted for their potential confounding effects in bivariable analyses. Subgroup analyses were subsequently performed to determine the potential differences in associations between IRI degree and the risk of HCC recurrence according to patients' initial risk profile, based on fulfilment of selection criteria and established independent predictors of recurrence.

Continuous and categorical variables are given as medians (interquartile ranges) and numbers (percentages). The Kaplan-Meier method was used for survival calculations, and log-rank test was used for intergroup comparisons. A Cox proportional hazards regression analysis was performed to evaluate the associations between particular factors and the risk of recurrence. A multivariable model was created using forward stepwise method with p thresholds of 0.05 and 0.150 for inclusion and exclusion of variables, respectively. An additional series of bivariable analyses were performed to adjust the effects of IRI to potential confounding effects of independent risk factors for tumour recurrence. Spearman correlation coefficients were calculated to evaluate the associations between ischemic times and donor age and post-reperfusion laboratory measurements. Post-reperfusion AST, ALT, and LDH levels; peak post-transplant bilirubin concentration; and peak post-transplant GGTP activity were transformed to their natural logarithms prior to their analyses as continuous variables. Additionally, they were assessed as categorical factors using the upper quartile for division. Receiver operating characteristic (ROC) curves were constructed to determine the optimal cut-offs of continuous factors in predicting recurrence. Hazard ratios (HRs) and c-statistics were presented with 95% confidence intervals (95% CIs). Significance threshold was set to two-tailed p values of 0.05. Analyses were computed in STATISTICA version 13 (Dell Inc., Tulsa, USA) software. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Results {#Sec3}
=======

The characteristics of the 195 patients are shown in Table [1](#Tab1){ref-type="table"}. Median AST, ALT, and LDH levels assessed 2 h post-reperfusion were 850 U/L (interquartile range: 486--1625 U/L; range 153--14375 U/L), 566 U/L (interquartile range: 304--935 U/L; range 102--9912 U/L), and 2240 U/L (interquartile range: 1322--4670 U/L; range 385--38207 U/L), respectively. Post-reperfusion AST and ALT levels were significantly, yet poorly correlated, with total (both p = 0.001) and cold ischemic times (both p \< 0.001), whereas post-reperfusion LDH levels were poorly correlated with cold ischemic time (p = 0.031), intraoperative fresh frozen plasma transfusions (p = 0.002), and intraoperative packed red blood cell transfusions (p = 0.018, Table [2](#Tab2){ref-type="table"}). Donor age and warm ischemic times were not correlated with post-reperfusion AST, ALT, and LDH levels.Table 1Recipient, donor, and operative characteristics of 195 liver transplant recipients with hepatocellular carcinoma included in the study.VariablesNumber (%) or median (IQR)Post-reperfusion AST (U/L)850 (486--1625)Post-reperfusion ALT (U/L)566 (304--935)Post-reperfusion LDH (U/L)2240 (1322--4670)Peak 7-day postoperative bilirubin concentration (mg/dL)3.6 (2.1--5.6)Peak 7-day postoperative international normalized ratio1.5 (1.3--1.8)Peak 7-day postoperative GGTP activity (U/L)663 (396--967)**Recipient sex**  male146 (74.9%)  female49 (25.1%)Recipient age (years)58 (52--61)Hepatitis C virus infection132 (67.7%)Hepatitis B virus infection89 (45.6%)Model for End-stage Liver Disease11 (8--13)Within Milan criteria113 (57.9%)Within UCSF criteria136 (69.7%)Within Up-to-7 criteria144 (73.8%)Number of tumors1 (1--3)Diameter of the largest tumor (mm)30 (20--45)Total tumor volume (cm^3^)22 (5--62)Alpha-fetoprotein concentration (ng/ml)13.8 (5.7--112.8)Microvascular invasion52 (26.7%)Poor tumor differentiation19 (9.7%)Neoadjuvant treatment102 (52.3%)Total ischemic time (hours)9.0 (8.0--10.3)Cold ischemic time (hours)8.0 (6.9--9.5)Warm ischemic time (minutes)55 (44--68)Intraoperative PRBC transfusions (units)3 (1--6)Intraoperative FFP transfusions (units)6 (4--9)Donor age51 (41--60)**Donor sex**  male120 (61.5%)  female75 (38.5%)IQR -- interquartile range; AST -- aspartate transaminase; ALT -- alanine transaminase; LDH -- lactate dehydrogenase; UCSF -- University of California, San Francisco; PRBC -- packed red blood cells; FFP -- fresh frozen plasma.Table 2Analyses of correlations between selected factors and activity of aspartate transaminase (AST), alaninę transaminase (ALT), and lactate dehydrogenase (LDH) at 2 hours after reperfusion in liver transplantation for hepatocellular carcinoma.AST activityALT activityLDH activityRpRpRpTotal ischemic time0.2410.0010.2440.0010.1320.082Cold ischemic time0.324\<0.0010.312\<0.0010.1880.031Warm ischemic time0.0830.3240.1020.2220.1240.155Intraoperative PRBC transfusions0.1070.1430.1250.0860.1790.018Intraoperative FFP transfusions0.0420.5650.0550.4490.2350.002Donor age0.0100.8920.0170.815−0.1200.108Correlations were assessed with Spearman correlation coefficients. AST -- aspartate transaminase; ALT -- alanine transaminase; LDH -- lactate dehydrogenase; PRBC -- packed red blood cells; FFP -- fresh frozen plasma.

The median follow-up period was 37.5 months. A total of 27 patients developed HCC recurrence with recurrence-free survival rates of 90.8%, 83.4%, and 81.0% at 1, 3, and 5 years, respectively. Univariable analyses revealed that post-reperfusion AST (p = 0.521), ALT (p = 0.773), and LDH (p = 0.575) levels and peak 7-day post-transplant bilirubin concentration (p = 0.592), INR (p = 0.553), and GGTP activity (p = 0.534) were not significantly associated with recurrence in all patients (Table [3](#Tab3){ref-type="table"}). There were also no significant differences in recurrence-free survival depending on the quartile of AST (p = 0.725), ALT (p = 0.819), and LDH (p = 0.656) levels (Fig. [1](#Fig1){ref-type="fig"}). Similarly, no differences with respect to recurrence-free survival were observed depending on the quartile of peak 7-day postoperative bilirubin concentration (p = 0.849), INR (p = 0.309), and GGTP activity (p = 0.866; Fig. [2](#Fig2){ref-type="fig"}). In multivariable analysis, the independent risk factors comprised tumour number (p = 0.004), pre-transplant alpha-fetoprotein concentration (p \< 0.001), presence of microvascular invasion (p = 0.014), and poor tumour differentiation (p = 0.007). No significant effects of post-reperfusion AST (all p \> 0.250), ALT (all p \> 0.403), and LDH (all p \> 0.176) levels and peak 7-day postoperative bilirubin concentration (all p \> 0.167), INR (all p \> 0.230), and GGTP activity (all p \> 0.123) on the risk of recurrence were found in analyses adjusted for the effects of these independent predictors. The corresponding series of bivariable analyses are presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. Additionally, fulfilment of the Milan (p \< 0.001; HR 0.17, 95% CI 0.07--0.43); University of California, San Francisco (UCSF, p = 0.009; HR 0.37, 95% CI 0.17--0.78); and Up-to-7 (p \< 0.001; HR 0.24, 95% CI 0.11--0.51) criteria significantly reduced the risk of recurrence.Table 3Analyses of risk factors for hepatocellular carcinoma recurrence after deceased donor liver transplantation.FactorsUnivariableMultivariableHR (95% CI)pHR (95% CI)pPost-reperfusion AST activity (continuous)1.17 (0.72--1.89)0.521Post-reperfusion AST activity (upper quartile)1.23 (0.52--2.91)0.638Post-reperfusion ALT activity (continuous)1.07 (0.67--1.72)0.773Post-reperfusion ALT activity (upper quartile)0.77 (0.29--2.04)0.602Post-reperfusion LDH activity (continuous)1.13 (0.73--1.76)0.575Post-reperfusion LDH activity (upper quartile)1.66 (0.73--3.78)0.226Peak postoperative bilirubin concentration (continuous)0.86 (0.51--1.47)0.592Peak postoperative bilirubin concentration (upper quartile)0.67 (0.25--1.78)0.424Peak postoperative INR (continuous)0.81 (0.41--1.60)0.553Peak postoperative INR (upper quartile)0.91 (0.34--2.42)0.854Post-reperfusion GGTP activity (continuous)1.20 (0.67--2.15)0.534Post-reperfusion GGTP activity (upper quartile)1.36 (0.59--3.12)0.474Total ischemic time1.02 (0.83--1.24)0.866Cold ischemic time1.07 (0.85--1.35)0.544Warm ischemic time1.00 (0.84--1.19)0.963Donor age1.00 (0.97--1.03)0.896Male donor sex0.52 (0.24--1.12)0.095Number of tumors1.25 (1.12--1.41)\<0.0011.21 (1.06--1.39)0.004Diameter of the largest tumor1.02 (1.01--1.03)0.001Total tumor volume1.01 (1.00--1.03)0.170Alpha-fetoprotein concentration1.31 (1.15--1.50)\<0.0011.29 (1.12--1.47)\<0.001Microvascular invasion4.28 (1.99--9.24)\<0.0012.67 (1.22--5.84)0.014Poor tumor differentiation4.05 (1.71--9.59)0.0023.35 (1.38--8.13)0.007Neoadjuvant treatment2.04 (0.91--4.54)0.082Male recipient sex0.64 (0.29--1.42)0.269Recipient age1.01 (0.96--1.05)0.809Hepatitis C virus infection0.89 (0.41--1.95)0.770Hepatitis B virus infection1.16 (0.54--2.47)0.703Model for End-stage Liver Disease0.93 (0.84--1.03)0.186Intraoperative PRBC transfusions0.99 (0.92--1.07)0.839Intraoperative FFP transfusions0.97 (0.89--1.05)0.470Hazard ratios for continuous variables are given per: 1 log~e~ (U/L) increase for AST, ALT, LDH, and GGTP activity; 1 increase for INR; 1 hour increase for total and cold ischemic times; 10 minute increase for warm ischemic time; 1 year increase for recipient and donor age; 1 increase for tumor number; 1 mm increase for diameter of the largest tumor; 10 cm^3^ increase for total tumor volume; 1 log~e~ (ng/ml) increase for alpha-fetoprotein concentration; 1 point increase for Model for End-stage Liver Disease; and 1 unit increase for transfusions. HR - hazard ratio; 95% CI -- 95% confidence interval; AST -- aspartate transaminase; ALT -- alanine transaminase; GGTP -- gamma-glutamyl transpeptidase; INR -- international normalized ratio; LDH -- lactate dehydrogenase; PRBC -- packed red blood cells; FFP -- fresh frozen plasmaFigure 1Recurrence-free survival of hepatocellular carcinoma patients after liver transplantation according to quartiles of aspartate transaminase (**A**), alanine transaminase (**B**), and lactate dehydrogenase (**C**) activity 2 hours after portal reperfusion.Figure 2Recurrence-free survival of hepatocellular carcinoma patients after liver transplantation according to quartiles of peak 7-day postoperative bilirubin concentration (**A**), international normalized ratio (**B**), and gamma-glutamyl transpeptidase activity (**C**).Table 4Analyses of the effects of the degree of ischemia-reperfusion injury on the risk of hepatocellular carcinoma recurrence after liver transplantation adjusted for the confounding influence of independent risk factors.FactorHR95% CIpAdjusted for the effects of:Post-reperfusion AST activity (continuous)1.100.70--1.740.683Tumor numberPost-reperfusion AST activity (categorical)1.200.51--2.850.677Tumor numberPost-reperfusion AST activity (continuous)1.110.70--1.740.667Alpha-fetoprotein concentrationPost-reperfusion AST activity (categorical)1.100.46--2.620.825Alpha-fetoprotein concentrationPost-reperfusion AST activity (continuous)1.310.76--2.250.332Microvascular invasionPost-reperfusion AST activity (categorical)1.670.70--3.990.250Microvascular invasionPost-reperfusion AST activity (continuous)1.250.75--2.090.398Poor tumor differentiationPost-reperfusion AST activity (categorical)1.430.60--3.410.425Poor tumor differentiationPost-reperfusion ALT activity (continuous)1.020.64--1.620.931Tumor numberPost-reperfusion ALT activity (categorical)0.710.27--1.870.483Tumor numberPost-reperfusion ALT activity (continuous)0.960.61--1.510.856Alpha-fetoprotein concentrationPost-reperfusion ALT activity (categorical)0.660.25--1.750.403Alpha-fetoprotein concentrationPost-reperfusion ALT activity (continuous)1.140.70--1.870.595Microvascular invasionPost-reperfusion ALT activity (categorical)0.900.34--2.370.827Microvascular invasionPost-reperfusion ALT activity (continuous)1.080.65--1.790.766Poor tumor differentiationPost-reperfusion ALT activity (categorical)0.890.33--2.390.824Poor tumor differentiationPost-reperfusion LDH activity (continuous)1.180.78--1.810.435Tumor numberPost-reperfusion LDH activity (categorical)1.690.74--3.850.211Tumor numberPost-reperfusion LDH activity (continuous)1.060.69--1.630.782Alpha-fetoprotein concentrationPost-reperfusion LDH activity (categorical)1.770.77--4.060.176Alpha-fetoprotein concentrationPost-reperfusion LDH activity (continuous)1.060.69--1.650.784Microvascular invasionPost-reperfusion LDH activity (categorical)1.310.57--3.030.521Microvascular invasionPost-reperfusion LDH activity (continuous)1.090.70--1.690.709Poor tumor differentiationPost-reperfusion LDH activity (categorical)1.410.61--3.270.427Poor tumor differentiationHR -- hazard ratio; 95% CI -- 95% confidence interval; AST -- aspartate transaminase; ALT -- alanine transaminase; LDH -- lactate dehydrogenase.Table 5Analyses of the associations between peak 7-day postoperative bilirubin concentration, INR value, and GGTP activity and the risk of hepatocellular carcinoma recurrence after liver transplantation adjusted for the confounding influence of independent risk factors.FactorHR95% CIpAdjusted for the effects of:Peak postoperative bilirubin concentration (continuous)0.780.47--1.280.324Tumor numberPeak postoperative bilirubin concentration (categorical)0.490.18--1.350.167Tumor numberPeak postoperative bilirubin concentration (continuous)0.890.54--1.460.641Alpha-fetoprotein concentrationPeak postoperative bilirubin concentration (categorical)0.690.26--1.850.465Alpha-fetoprotein concentrationPeak postoperative bilirubin concentration (continuous)0.810.48--1.390.453Microvascular invasionPeak postoperative bilirubin concentration (categorical)0.630.24--1.670.349Microvascular invasionPeak postoperative bilirubin concentration (continuous)0.830.48--1.460.526Poor tumor differentiationPeak postoperative bilirubin concentration (categorical)0.710.27--1.900.500Poor tumor differentiationPeak postoperative INR (continuous)0.640.31--1.320.230Tumor numberPeak postoperative INR (categorical)0.750.28--2.010.564Tumor numberPeak postoperative INR (continuous)0.660.33--1.350.258Alpha-fetoprotein concentrationPeak postoperative INR (categorical)0.770.29--2.060.603Alpha-fetoprotein concentrationPeak postoperative INR (continuous)0.720.32--1.600.420Microvascular invasionPeak postoperative INR (categorical)0.780.29--2.080.620Microvascular invasionPeak postoperative INR (continuous)0.860.42--1.740.673Poor tumor differentiationPeak postoperative INR (categorical)1.230.44--3.410.696Poor tumor differentiationPeak postoperative GGTP activity (continuous)1.240.67--2.290.488Tumor numberPeak postoperative GGTP activity (categorical)1.420.61--3.260.415Tumor numberPeak postoperative GGTP activity (continuous)1.580.83--2.990.164Alpha-fetoprotein concentrationPeak postoperative GGTP activity (categorical)2.000.83--4.840.123Alpha-fetoprotein concentrationPeak postoperative GGTP activity (continuous)1.280.70--2.340.422Microvascular invasionPeak postoperative GGTP activity (categorical)1.530.66--3.540.321Microvascular invasionPeak postoperative GGTP activity (continuous)1.120.62--2.010.709Poor tumor differentiationPeak postoperative GGTP activity (categorical)1.230.53--2.830.634Poor tumor differentiationHazard ratios for continuous variables are given per: 1 mg/dL increase for bilirubin concentration; 1 increase for INR; 1 log~e~ (U/L) increase for GGTP activity. HR -- hazard ratio; 95% CI -- 95% confidence interval; INR -- international normalized ratio; GGTP -- gamma-glutamyl transpeptidase

For further analyses, the patients were divided into subgroups based on the fulfilment of selection criteria and independent predictors of recurrence. Cut-offs for tumour number of ≥3 and alpha-fetoprotein concentration of ≥48.3 ng/ml were derived from the corresponding ROC curves. As a continuous variable, post-reperfusion AST significantly influenced the risk of HCC recurrence only in patients within the Milan criteria (p = 0.035, Table [6](#Tab6){ref-type="table"}) with the optimal cut-off of ≥1896 U/L. Additionally, post-reperfusion AST and LDH levels exceeding the upper quartiles were significantly associated with increased risk of recurrence in patients either within the Milan (p = 0.039 and p = 0.040, respectively) or Up-to-7 (p = 0.028 and p = 0.039, respectively) criteria. The degree of IRI, as reflected by post-reperfusion AST, ALT, and LDH levels, did not significantly influence the HCC recurrence risk in patients within the UCSF criteria or in those beyond the Milan, UCSF, or Up-to-7 criteria. No other significant associations between post-reperfusion AST, ALT, and LDH levels and the risk of post-transplant tumour recurrence were observed in subgroups derived from divisions based on tumour number, alpha-fetoprotein concentration, presence of microvascular invasion, and degree of tumour differentiation. In contrast to the significant effects of IRI in patients within the Milan or Up-to-7 criteria, no effects were found for the duration of total ischemia (all p \> 0.701), cold ischemia (all p \> 0.417), warm ischemia (all p \> 0.373), and donor age (all p \> 0.276) in these subgroups (Table [7](#Tab7){ref-type="table"}). No significant associations between peak 7-day postoperative bilirubin concentration (all p \> 0.081), INR (all p \> 0.205), and GGTP activity (p \> 0.097) and HCC recurrence risk were identified in subgroup analyses (Table [8](#Tab8){ref-type="table"}).Table 6Subgroup analyses of the associations between post-reperfusion aspartate transaminase, alanine transaminase, and lactate dehydrogenase activity and the risk of hepatocellular carcinoma recurrence after liver transplantation according to fulfillment of selection criteria and independent risk factors.FactorSubgroup of patientsAnalyzed as continuous variable: per log~e~ (U/L) increaseAnalyzed as categorical variable: Q4 versus Q1-Q3AST activityWithin Milan criteria2.75 (1.07--7.03)0.0355.99 (1.10--32.78)0.039AST activityBeyond Milan criteria0.86 (0.47--1.55)0.6060.71 (0.21--2.43)0.591AST activityWithin UCSF criteria1.67 (0.84--3.30)0.1412.79 (0.94--8.33)0.065AST activityBeyond UCSF criteria0.84 (0.40--1.75)0.6400.36 (0.05--2.77)0.327AST activityWithin Up-to-7 criteria1.91 (0.94--3.90)0.0733.58 (1.15--11.11)0.028AST activityBeyond Up-to-7 criteria0.80 (0.41--1.55)0.5000.24 (0.03--1.82)0.167AST activityTumor number \<31.58 (0.81--3.09)0.1832.22 (0.72--6.80)0.164AST activityTumor number ≥30.81 (0.38--1.70)0.5720.62 (0.14--2.79)0.536AST activityAFP \< 48.3 ng/ml1.51 (0.68--3.33)0.3091.06 (0.23--5.02)0.937AST activityAFP ≥ 48.3 ng/ml0.92 (0.50--1.70)0.8011.04 (0.37--2.97)0.936AST activityWithout MVI1.37 (0.67--2.80)0.3862.58 (0.79--8.47)0.117AST activityWith MVI1.18 (0.51--2.71)0.6940.89 (0.20--3.95)0.882AST activityWell or moderately differentiated tumors1.22 (0.71--2.11)0.4781.11 (0.40--3.05)0.842AST activityPoorly differentiated tumors1.66 (0.34--8.03)0.5263.95 (0.75--20.76)0.104ALT activityWithin Milan criteria2.41 (0.88--6.61)0.0873.15 (0.63--15.78)0.163ALT activityBeyond Milan criteria0.84 (0.47--1.50)0.5510.43 (0.10--1.84)0.254ALT activityWithin UCSF criteria1.22 (0.62--2.41)0.5711.02 (0.28--3.73)0.974ALT activityBeyond UCSF criteria0.97 (0.48--1.94)0.9240.62 (0.14--2.76)0.527ALT activityWithin Up-to-7 criteria1.37 (0.66--2.83)0.3981.25 (0.34--4.66)0.735ALT activityBeyond Up-to-7 criteria0.89 (0.48--1.68)0.7280.40 (0.09--1.80)0.233ALT activityTumor number \<31.14 (0.58--2.24)0.6990.63 (0.14--2.87)0.555ALT activityTumor number ≥30.97 (0.48--1.97)0.9340.89 (0.25--3.18)0.852ALT activityAFP \< 48.3 ng/ml1.35 (0.60--3.04)0.4690.99 (0.21--4.65)0.986ALT activityAFP ≥ 48.3 ng/ml0.85 (0.48--1.51)0.5820.52 (0.15--1.82)0.308ALT activityWithout MVI1.31 (0.63--2.72)0.4661.23 (0.33--4.64)0.761ALT activityWith MVI1.00 (0.52--1.96)0.9890.63 (0.14--2.77)0.540ALT activityWell or moderately differentiated tumors1.02 (0.59--1.75)0.9420.79 (0.26--2.37)0.676ALT activityPoorly differentiated tumors1.67 (0.34--8.13)0.5261.80 (0.21--15.23)0.589LDH activityWithin Milan criteria1.93 (0.75--4.97)0.1756.08 (1.09--33.95)0.040LDH activityBeyond Milan criteria0.88 (0.54--1.43)0.6020.85 (0.31--2.38)0.764LDH activityWithin UCSF criteria1.33 (0.72--2.45)0.3632.75 (0.91--8.27)0.073LDH activityBeyond UCSF criteria0.90 (0.49--1.66)0.7370.74 (0.20--2.77)0.658LDH activityWithin Up-to-7 criteria1.68 (0.86--3.31)0.1303.33 (1.06--10.40)0.039LDH activityBeyond Up-to-7 criteria0.80 (0.47--1.37)0.4200.57 (0.15--2.10)0.398LDH activityTumor number \<31.21 (0.59--2.45)0.6042.33 (0.76--7.15)0.140LDH activityTumor number ≥ 31.04 (0.61--1.76)0.8891.03 (0.31--3.44)0.964LDH activityAFP \< 48.3 ng/ml1.16 (0.54--2.52)0.6981.66 (0.42--6.67)0.472LDH activityAFP ≥ 48.3 ng/ml1.01 (0.61--1.68)0.9631.49 (0.53--4.14)0.449LDH activityWithout MVI1.15 (0.59--2.27)0.6802.13 (0.62--7.35)0.231LDH activityWith MVI0.99 (0.56--1.75)0.9760.90 (0.30--2.73)0.856LDH activityWell or moderately differentiated tumors1.11 (0.66--1.85)0.7031.93 (0.76--4.92)0.169LDH activityPoorly differentiated tumors1.05 (0.43--2.54)0.9220.59 (0.10--3.33)0.547Q4 -- fourth quartile; Q1-Q3 -- first to third quartile; AST -- aspartate transaminase; ALT -- alanine transaminase; LDH -- lactate dehydrogenase; UCSF -- University of California, San Francisco; AFP -- alpha-fetoprotein; MVI -- microvascular invasion.Table 7Analyses of the associations between allograft ischemia and donor age and the risk of hepatocellular carcinoma recurrence after liver transplantation in patient within Milan and Up-to-7 criteria.FactorSubgroup of patientsAnalyzed as continuous variable:Analyzed as categorical variable: Q4 versus Q1-Q3HR (95% CI)pHR (95% CI)pTotal ischemiaWithin Milan criteria1.03 (0.69--1.54)0.8931.39 (0.26--7.62)0.701Total ischemiaWithin Up-to-7 criteria1.05 (0.77--1.41)0.7691.01 (0.27--3.72)0.991Cold ischemiaWithin Milan criteria1.14 (0.69--1.87)0.6112.25 (0.32--16.06)0.417Cold ischemiaWithin Up-to-7 criteria1.08 (0.76--1.55)0.6651.50 (0.36--6.30)0.577Warm ischemiaWithin Milan criteria0.78 (0.42--1.48)0.452---^a^0.373^a^Warm ischemiaWithin Up-to-7 criteria0.98 (0.70--1.37)0.9080.52 (0.06--4.26)0.544Donor ageWithin Milan criteria1.04 (0.97--1.13)0.2761.71 (0.31--9.54)0.541Donor ageWithin Up-to-7 criteria1.01 (0.96--1.06)0.6871.03 (0.28--3.84)0.960Q4 -- fourth quartile; Q1-Q3 -- first to third quartile; HR -- hazard ratio; 95% CI -- 95% confidence interval. Hazard ratios for continuous variables are given per 1 log~e~(U/L) increase. Compared with log-rank test, 100% versus 89.4% recurrence free survival at 5 years in Q4 and Q1--Q3 patients, respectively.Table 8Subgroup analyses of the associations between peak 7-day postoperative bilirubin concentration, INR value, and GGTP activity and the risk of hepatocellular carcinoma recurrence after liver transplantation according to fulfillment of selection criteria and independent risk factors.FactorSubgroup of patientsAnalyzed as continuous variable: per log~e~ (U/L) increaseAnalyzed as categorical variable: Q4 versus Q1-Q3BilirubinWithin Milan criteria1.59 (0.50--5.10)0.4361.37 (0.25--7.48)0.717BilirubinBeyond Milan criteria0.74 (0.41--1.34)0.3180.50 (0.15--1.72)0.275BilirubinWithin UCSF criteria1.23 (0.58--2.65)0.5890.95 (0.26--3.46)0.940BilirubinBeyond UCSF criteria0.56 (0.26--1.22)0.1420.42 (0.09--1.88)0.254BilirubinWithin Up-to-7 criteria1.56 (0.67--3.61)0.3000.98 (0.27--3.63)0.978BilirubinBeyond Up-to-7 criteria0.53 (0.26--1.08)0.0810.42 (0.09--1.90)0.263BilirubinTumor number \<31.18 (0.55--2.54)0.6660.95 (0.26--3.47)0.942BilirubinTumor number ≥30.59 (0.28--1.24)0.1630.42 (0.09--1.89)0.256BilirubinAFP \< 48.3 ng/ml0.61 (0.26--1.44)0.2620.68 (0.14--3.18)0.620BilirubinAFP ≥ 48.3 ng/ml1.02 (0.51--2.05)0.9520.72 (0.20--2.56)0.617BilirubinWithout MVI0.62 (0.28--1.41)0.2590.31 (0.04--2.43)0.266BilirubinWith MVI1.00 (0.50--2.01)0.9970.87 (0.28--2.72)0.805BilirubinWell or moderately differentiated tumors1.01 (0.55--1.86)0.9750.73 (0.24--2.20)0.577BilirubinPoorly differentiated tumors0.35 (0.08--1.45)0.1490.68 (0.08--5.66)0.717INRWithin Milan criteria1.21 (0.23--6.21)0.8231.16 (0.13--9.92)0.894INRBeyond Milan criteria0.58 (0.25--1.35)0.2050.55 (0.19--1.66)0.292INRWithin UCSF criteria0.82 (0.25--2.68)0.7470.97 (0.21--4.38)0.968INRBeyond UCSF criteria0.65 (0.25--1.69)0.3800.61 (0.17--2.22)0.452INRWithin Up-to-7 criteria0.90 (0.26--3.08)0.8611.04 (0.23--4.75)0.960INRBeyond Up-to-7 criteria0.56 (0.22--1.46)0.2400.48 (0.13--1.71)0.255INRTumor number \<30.64 (0.14--2.92)0.5690.80 (0.18--3.62)0.774INRTumor number ≥30.77 (0.37--1.59)0.4740.91 (0.25--3.31)0.881INRAFP \< 48.3 ng/ml1.12 (0.36--3.50)0.8431.92 (0.50--7.45)344INRAFP ≥ 48.3 ng/ml0.53 (0.19--1.48)0.2250.39 (0.09--1.73)0.218INRWithout MVI0.38 (0.06--2.52)0.3180.46 (0.06--3.63)0.464INRWith MVI0.93 (0.37--2.30)0.8691.01 (0.32--3.19)0.990INRWell or moderately differentiated tumors0.93 (0.48--1.78)0.8171.24 (0.45--3.45)0.678INRPoorly differentiated tumors0.17 (0/01--7.11)0.351------GGTPWithin Milan criteria1.55 (0.48--5.02)0.4672.87 (0.58--14.24)0.196GGTPBeyond Milan criteria1.09 (0.53--2.26)0.8181.09 (0.40--3.02)0.862GGTPWithin UCSF criteria1.44 (0.66--3.14)0.3611.97 (0.64--6.01)0.236GGTPBeyond UCSF criteria0.84 (0.32--2.25)0.7320.82 (0.22--2.97)0.758GGTPWithin Up-to-7 criteria1.41 (0.61--3.21)0.4202.14 (0.68--6.75)0.193GGTPBeyond Up-to-7 criteria1.00 (0.38--2.60)0.9920.86 (0.24--3.11)0.823GGTPTumor number \<31.76 (0.77--4.00)0.1772.06 (0.67--6.29)0.207GGTPTumor number ≥30.63 (0.25--1.58)0.3210.77 (0.21--2.79)0.689GGTPAFP \< 48.3 ng/ml2.47 (0.85--7.21)0.0972.40 (0.69--8.28)0.167GGTPAFP ≥ 48.3 ng/ml1.04 (0.48--2.25)0.9151.55 (0.44--5.51)0.499GGTPWithout MVI0.95 (0.41--2.22)0.9101.02 (0.27--3.84)0.979GGTPWith MVI1.78 (0.77--4.11)0.1792.22 (0.74--6.65)0.154GGTPWell or moderately differentiated tumors1.36 (0.68--2.69)0.3851.47 (0.56--3.88)0.433GGTPPoorly differentiated tumors0.71 (0.22--2.23)0.5550.80 (0.15--4.14)0.789Hazard ratios for continuous variables are given per: 1 mg/dL increase for bilirubin concentration; 1 increase for INR; 1 log~e~ (U/L) increase for GGTP activity. Q4 -- fourth quartile; Q1-Q3 -- first to third quartile; INR -- international normalized ratio; GGTP -- gamma-glutamyl transpeptidase; AFP -- alpha-fetoprotein; MVI -- microvascular invasion.

In patients within the Milan criteria, recurrence-free survival at 1, 3, and 5 years was 98.8%, 96.6%, and 96.6%, respectively, when post-reperfusion AST level was \<1896 U/L as opposed to 86.2%, 86.2%, and 71.9% at 1, 3, and 3.7 years, respectively, when post-reperfusion AST level was ≥1896 U/L (p = 0.006, Fig. [3A](#Fig3){ref-type="fig"}). Similarly, patients within the Milan criteria and with post-reperfusion LDH level \<4670 U/L exhibited 5-year recurrence-free survival of 97.4%, which was significantly higher (p = 0.016) than the 1-, 3-, and 5-year rates of 90.2%, 84.2%, and 78.2%, respectively, observed for those within the Milan criteria and with post-reperfusion LDH level ≥4670 U/L (Fig. [3B](#Fig3){ref-type="fig"}). Significant differences with respect to 5-year recurrence-free survival depending on post-reperfusion AST (p = 0.027) and LDH (p = 0.031) levels were also observed for patients within the Up-to-7 criteria (Fig. [3C,D](#Fig3){ref-type="fig"}).Figure 3Recurrence-free survival after liver transplantation for hepatocellular carcinoma in patients within Milan criteria (**A**,**B**) and Up-to-7 criteria (**C**,**D**) according to post-reperfusion aspartate transaminase and lactate dehydrogenase activity.

Discussion {#Sec4}
==========

In the era of donor shortage and increasing utilization of high-risk grafts to partly ameliorate its negative effects, the problem of potential association between the degree of IRI and the risk of HCC recurrence after liver transplantation is of utmost importance. According to the available results of experimental studies, hepatic IRI, universally present in the setting of liver transplantation, increases the risk of metastasis formation both within the ischemic and remote sites through changes in the local microenvironment, induction of inflammatory response, induction of metastatic potential of circulating cancer cells, and systemic release of pro-tumourigenic cytokines^[@CR12]--[@CR16]^. Our study results demonstrate a major negative effect of IRI on the risk of post-transplant HCC recurrence, although limited to patients with low tumour burden.

Importantly, initial analyses performed in all patients failed to reveal any significant associations between post-reperfusion AST, ALT, and LDH levels and HCC recurrence risk, irrespective whether the factors were analysed as continuous or categorical variables. However, the study cohort comprised patients with a wide range of tumour burden due to a liberal selection policy utilised in the authors' department before establishment of precise criteria^[@CR5]^. Nevertheless, a major significant negative effect of post-reperfusion AST and LDH levels was observed for patients within the Milan criteria, which still determine the majority of liver transplant recipients^[@CR28]^. Similar findings, although of remarkably lesser extent, were found for patients within the Up-to-7 criteria, whereas the magnitude of IRI did not influence the risk of recurrence in patients beyond the extended criteria. This indicates that the clinical relevance of IRI is limited to generally low-risk populations and diminishes with increasing tumour burden. This appears to be particularly importantly because it demonstrates the possibility of using high-risk grafts to expand the donor pool for high-risk HCC candidates in the context of discussion on widening the boundaries of existing selection criteria^[@CR2]--[@CR6],[@CR29]^. Notably, the safe use of extended criteria allografts preferentially for patients with advanced tumours was already reported^[@CR30]^. Conversely, none of the subgroup analyses performed in high-risk patients, including those beyond particular selection criteria, with ≥3 tumours, alpha-fetoprotein concentration ≥48.3 ng/mL, or with tumours either poorly differentiated or with microvascular invasion, revealed a significant effect of IRI on the risk of HCC recurrence. Therefore, while these findings point toward the possibility of the utilization of grafts more prone to IRI for high-risk HCC patients, they also indicate limited clinical relevance of reducing IRI in these patients.

In contrast to the use of post-reperfusion transaminases and LDH levels as surrogates of IRI degree in the present study, previous studies focused on the negative effects of prolonged graft ischemia or donor characteristics^[@CR17]--[@CR25],[@CR31]^. However, the degree of IRI is driven by the interplay of several donor risk factors, of which a single component may not necessarily be an adequate measure of IRI^[@CR32]^. In the present study, the laboratory measures of graft ischemia were significantly, yet poorly correlated to graft ischemic times, which in fact is consistent with the results presented by other authors^[@CR25]^. This may partly explain the inconsistent results of studies on the effect of duration of graft ischemia and particular donor factors on HCC recurrence risk, as these may not always accurately reflect the magnitude of IRI^[@CR17]--[@CR25],[@CR31]^.

In contrast to the significant effects of IRI limited to low-risk patients found in the present study, two previous analyses specifically aimed at the effect of ischemic times on tumour recurrence revealed the presence of significant associations particularly in high-risk HCC patients^[@CR24],[@CR25]^. These populations were characterised by ^18^F-fluorodeoxyglucose tumour avidness on pre-transplant positron emission tomography and vascular invasion, both of which are known surrogates of biological aggressiveness. Although positron emission tomography data were not available, categorization of patients based on pre-transplant alpha-fetoprotein concentration and tumour differentiation, which are important markers of tumour biology, did not reveal any significant effects of IRI and neither did the analyses stratified for microvascular invasion. The reason for this discrepancy is unclear, although it may be related to a wider spectrum of tumour burden in patients included in the present study. Of note, post-operative peak transaminases did not emerge as risk factors for HCC recurrence in these previous reports. However, we chose post-reperfusion AST, ALT, and LDH levels routinely assessed in our department and not peak levels over the postoperative period in order to minimise the effect of events other than IRI on these parameters.

The results of the present study point toward the importance of strategies aimed to decrease IRI particularly for patients within the standard selection criteria. A single retrospective study revealed decreased magnitude of IRI, as illustrated by low transaminase levels and decreased risk of HCC recurrence in patients receiving prostaglandin E1 analog alprostadil in the early period after liver transplantation^[@CR33]^. The protective effects of ischemic preconditioning with respect to the development of metastases were also reported in a recent experimental study^[@CR14]^. The use of machine perfusion devices has also been shown to decrease the magnitude of IRI and recently even enabled the development of a strategy to practically eliminate its negative consequences^[@CR34]--[@CR36]^. Although the present study does not provide any evidence for the effects of these measures in liver transplantation for HCC, it provides a rationale for prospective trials aimed at addressing this issue.

This study had several limitations besides those inherent to its retrospective nature. Donor characteristics other than a baseline variable of age were neither analysed for associations with post-reperfusion transaminase and LDH levels nor as predictors of tumour recurrence. However, such analyses were beyond the scope of this study, specifically aimed at the effect of IRI on post-transplant HCC recurrence rather than on its determinants. Because all recipients received grafts from donors after brain death, this study did not directly address the issue of using grafts from donors after cardiac death for HCC patients, which was recently shown not to increase the risk of post-transplant recurrence^[@CR23]^. Although subject to additional warm ischemia and thus potentially increased magnitude of IRI, their use in HCC patients may be confounded by other factors, including but not limited to, non-random allocation and differences in other donor characteristics. Furthermore, the duration of warm ischemia was not identified as a significant predictor of HCC recurrence. Finally, the main findings of our study are based on the results of univariable subgroup analyses. Therefore, the findings may be confounded by the effects of other risk factors for tumour recurrence. Although there was no particular policy at the authors' department for the allocation of high-risk grafts to higher-risk HCC patients, the results may also be confounded by non-random allocation of grafts more prone to IRI to patients within the Milan or Up-to-7 criteria, yet at higher initial recurrence risk.

In conclusion, the magnitude of IRI is strongly associated with the risk of tumour recurrence in patients within the Milan criteria and to a lesser extent, in patients within the extended criteria. Available measures to decrease IRI should be evaluated as a method to prevent HCC recurrence after liver transplantation, specifically in patients with low tumour burden.
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